RenovoRx, Inc.
RNXT- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001574094
In the last 90 days, RenovoRx, Inc. insiders filed 1 open-market purchase and 0 sales; 40 institutions reported holding it in 13F filings for Q3 2026, worth $19.1M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:53 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $11.2M (994.5% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 30, 2026 | Apr 1, 2025 | – | Mar 2, 2023 | Mar 30, 2022 |
| Revenue | $1.12M | $43.0K | – | – | – |
| Cost of revenue | $327.0K | – | – | – | – |
| Gross profit | $796.0K | $43.0K | – | – | – |
| Operating expenses | $13.3M | $11.0M | $11.4M | $9.95M | $5.67M |
| Research and development | $6.27M | $6.03M | $5.67M | $4.30M | $3.04M |
| Selling, general and administrative | $7.04M | $4.99M | $5.73M | $5.65M | $2.63M |
| Operating income | -$12.5M | -$11.0M | -$11.4M | -$9.95M | -$5.67M |
| Income tax | $2.00K | – | – | – | – |
| Net income | -$11.2M | -$8.81M | -$10.2M | -$9.89M | -$6.32M |
| EPS, basic | $-0.32 | $-0.40 | $-0.99 | $-1.09 | – |
| EPS, diluted | $-0.32 | $-0.40 | $-0.99 | – | – |
| Weighted shares, basic | 35.3M | 22.3M | 10.3M | 9.05M | – |
| Weighted shares, diluted | 35.3M | 22.3M | 10.3M | – | – |
| Margins and growth | |||||
| Gross margin | 70.9% | 100.0% | – | – | – |
| Operating margin | -1114.0% | -25511.6% | – | – | – |
| Net margin | -994.5% | -20497.7% | – | – | – |
| Revenue growth, year over year | +2,511.6% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 30, 2026 | Apr 1, 2025 | – | Mar 2, 2023 | Mar 30, 2022 |
| Cash and equivalents | $7.02M | $7.15M | $1.17M | $4.39M | $15.2M |
| Short-term investments | – | – | – | $2.05M | – |
| Accounts receivable | $139.0K | $43.0K | – | – | – |
| Inventory | $189.0K | – | – | – | – |
| Total current assets | $7.89M | $7.83M | – | $7.26M | $16.3M |
| Property, plant and equipment | $12.0K | $12.0K | – | – | – |
| Total assets | $8.10M | $8.12M | $1.47M | $7.26M | $16.3M |
| Accounts payable | $799.0K | $586.0K | $561.0K | $534.0K | $525.0K |
| Total current liabilities | $1.96M | $1.91M | $1.18M | – | $938.0K |
| Total liabilities | $2.67M | $3.64M | $4.47M | $1.10M | $938.0K |
| Shareholders' equity | $5.42M | $4.48M | -$3.00M | $6.16M | $15.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 30, 2026 | Apr 1, 2025 | – | Mar 2, 2023 | Mar 30, 2022 |
| Operating cash flow | -$11.0M | -$9.13M | -$10.3M | -$8.81M | -$5.92M |
| Capital expenditures | $2.00K | $12.0K | – | – | – |
| Free cash flow | -$11.0M | -$9.14M | – | – | – |
| Depreciation and amortization | $2.00M | – | – | – | – |
| Stock-based compensation | $1.27M | $1.17M | $1.08M | $644.0K | $147.0K |
| Investing cash flow | -$2.00K | -$12.0K | $2.03M | -$2.03M | -$15.0K |
| Financing cash flow | $10.8M | $15.1M | $5.01M | $42.0K | $19.3M |
| Net change in cash | -$130.0K | $5.98M | -$3.22M | -$10.8M | $13.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 112.8% | 2730.2% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 48.3M | +31.7% | SEC |
| Aug 7, 2026 | 45.1M | +23.2% | SEC |
| May 7, 2026 | 45.1M | +23.3% | SEC |
| Mar 23, 2026 | 45.1M | +23.3% | SEC |
| Nov 12, 2025 | 36.6M | +52.7% | SEC |
| Aug 11, 2025 | 36.6M | +52.8% | SEC |
| May 9, 2025 | 36.6M | +52.7% | SEC |
| Mar 25, 2025 | 36.5M | +116.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.